Avapritinib: a new tyrosine kinase inhibitor for treatment of advanced gastrointestinal stromal tumors. The literature review and clinical case
We have three drugs for treatment of gastrointestinal stromal tumors (GIST): imatinib, sunitinib and regorafenib. Avapritinib (Ayvakit, BLU-285) is one more drug that was approved in January 2020. Avapritinib is a new selective tyrosine kinase inhibitor of PDGFRA and KIT mutations. Based on NAVIGATO...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | article |
| Language: | RU |
| Published: |
IP Habib O.N.
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/6e46ed6345224af8a1b117b56a28b0d7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|